Loss Per Share - Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
		Dec. 31, 2020	Dec. 31, 2019
Earnings Per Share [Abstract]
Net loss - before noncontrolling interest		$ (35,888)	$ (17,268)
Net loss attributable to noncontrolling interest		1,612	811
Net loss - as reported, attributable to PAVmed Inc.		(34,276)	(16,457)
Series B Convertible Preferred Stock dividends - earned	[1]	(287)	(270)
Net loss attributable to PAVmed Inc. common stockholders		$ (34,563)	$ (16,727)
Weighted average common shares outstanding, basic and diluted	[2]	47,432,115	30,197,458
Basic and diluted - Net loss - as reported, attributable to PAVmed Inc.		$ (0.72)	$ (0.54)
Basic and diluted - Net loss attributable to PAVmed Inc. common stockholders		$ (0.73)	$ (0.55)

[1] The Series B Convertible Preferred Stock dividends earned as of the each of the respective periods noted, are included in the calculation of basic and diluted net loss attributable to PAVmed Inc. common stockholders for each respective period presented.

[2] Basic weighted-average number of shares of common stock outstanding for the years ended December 31, 2020 and 2019 include the shares of the Company issued and outstanding during the years ended December 31, 2020 and December 31, 2019, each on a weighted average basis. The basic weighted average number of shares outstanding excludes common stock equivalent incremental shares, while diluted weighted average number of shares outstanding includes such incremental shares. However, as the Company was in a loss position for all periods presented, basic and diluted weighted average shares outstanding are the same, as the inclusion of the incremental shares would be anti-dilutive.